Lower relapse incidence with HAPLO versus MSD or MUD HCTs for AML patients with KMT2A rearrangement: a study from the Global Committee and the ALWP of the EBMT.

A study published in the Blood Cancer Journal compared the use of different donor sources for hematopoietic stem cell transplants in adult patients with adverse-risk acute myeloid leukemia (AML) and KMT2A rearrangement. The study found that haploidentical donor transplants had a lower relapse incidence compared to matched sibling or unrelated donor transplants, suggesting potential benefits for AML patients with adverse-risk KMT2A rearrangement. The study also explored the impact of different fusion partners on prognosis. The article provides data on relapse incidence, non-relapse mortality, overall survival, leukemia-free survival, and graft-versus-host disease rates in AML patients undergoing hematopoietic cell transplantation. The study highlights the need for further research to improve transplant outcomes and reduce non-relapse mortality. [Extracted from the article]